TRIAL DETAIL

Study of AMG 706 in Subjects With Advanced Gastrointestinal Stromal Tumors (GISTs)

Drug:
Trial Name:
Study of AMG 706 in Subjects With Advanced Gastrointestinal Stromal Tumors (GISTs)
NCT#:
Conditions:
Gastrointestinal Stromal Tumor
Status:
Completed
Phase:
2
Start Date 10/01/2004
Age of Trial (yrs) 20.2
Treatment Phase:
Gleevec-resistant
Drug Category:
KIT/PDGFRA inhibitor VEGFR inhibitor (TKI)
Strategy:
Block KIT
Trial Type:
Specifically GIST and only GIST
Other Protocol IDs:
20040110
Sponsor:
Amgen Inc.
Patient Contact:
Contact email:
Contact Phone:
Randomized:
IV or Oral:
Oral
Trial Notes:
This trial is completed.
Conclusions of the authors were:
In this study of patients with imatinib-resistant GIST, motesanib treatment resulted in acceptable tolerability and modest tumor control as evident in the proportion of patients who achieved stable disease and durable stable disease.

Trial Links

Trial Results
 
 

Drug Information
AMG 706 - Cancer Research - Full text
 
Motesanib in thyroid cancer - NEJM
 
The Molecular Basis of Class Side Effects Due to Treatment with Inhibitors of the VEGF/VEGFR Pathway
 
Amgen pipeline-Motesanib
 
Motesanib inhibits Kit mutations associated with gastrointestinal stromal tumors. (full text article)
 

Trial Sites

Name
Address
City
State
Zip
Country